Infrastructure

The Unit is placed at SciLifeLab, Campus Solna, and it is hosted by DBB which also has a large number of structural biology groups that use the technique. 

Cryo-EM (cryogenic electron microscopy) is a technique that allows the direct visualisation of single macromolecules such as proteins and nucleic acids, as well as anything bigger (organelles or full thin cells). By combining a large number of images of macromolecules (particles), in the order of hundred of thousands to millions, three-dimensional (3D) densities and molecular models can be computed in a process known as Single Particle Analysis (SPA). 

It is also possible to image and reconstruct entire viruses, organelles or other cell compartments and gain ultrastructural information by using Cryo-electron tomography (cryo-ET).

Cryo-EM can also be used to collect electron diffraction data of micro- and nano-sized crystals (micro-ED) also with the aim of determining the 3D structure of proteins or chemical compounds. 

Micro-ED has been implemented at the SciLifeLab Cryo-EM Unit thanks to a strong and fruitful collaboration with the Zou’s and Xu’s groups at MMK. 

The Cryo-EM Infrastructure Unit offers access to state-of-the-art equipment and expertise in SPA, cryo-ET and micro-ED. 

The Cryo-EM Infrastructure Unit is equipped with:     
 

1. Titan Krios G2 (Thermo Fischer Scientific), equipped with a CetaD camera, and Falcon III and a Gatan/Ametek K3 BioQuantum electron detectors 
2. Titan Krios G3i (Thermo Fischer Scientific), equipped with a Ceta-D camera and a Gatan K3 BioQuantum detector
3. Talos Arctica equipped with Falcon III (Thermo Fischer Scientific), Gatan/Ametek K2 and Ceta CMOS 
4. All instruments are equipped with advanced software solutions for data acquisition both in imaging and diffraction mode
5. Two vitrobots markIV (Thermo Fischer Scientific) for sample preparation

The Cryo-EM Infrastructure Unit offers a service of consultation for image analysis and structure determination via a drop-in bookable service. The Unit is also working, in collaboration with NBIS and WABI (also DBB associated), to potentiate the support for Cryo-EM data analysis.

Access to the Infrastructure is available by registering to the portal (link below) or by contacting us (email below). All services are bookable and all projects trackable at the CryoEM-Sweden EMhub platform (link below).

We aim to provide:

1. An internationally competitive infrastructure that is accessible to all academic scientists in Sweden on equal terms.
2. A training environment where researchers can become familiar with cutting-edge methods in cryo-EM.
3. An educational framework of scientific meetings, practical workshops and training courses to enhance the activity of the broad Swedish scientific community.

The Cryo-EM Infrastructure Unit offers a unique service to the whole of Sweden.

The Unit is supported by SciLifeLab, the Knut and Alice Wallenberg Foundation, the Family Erling Persson Foundation and Stockholm University.

CONTACT:
Marta Carroni
marta.carroni@scilifelab.se
 

Cryo-EM Sweden Information and Application Portal

the CryoEM-Sweden EMhub platform

cryoEM_stockholm_lab@scilifelab.se

For more information, please see the Cryo-EM page on the SciLifeLab website:

Cryo-EM

National Bioinformatics Infrastructure Sweden (NBIS) is a distributed national infrastructure, supporting life scientists in Sweden with a range of services, including custom-tailored data analyses, data management, systems development and advanced training.

NBIS has staff at six sites (Gothenburg, Linköping, Lund, Stockholm, Uppsala, and Umeå). Most of the Stockholm staff are employed at DBB and located at SciLifeLab in Solna.

NBIS constitutes the SciLifeLab Bioinformatics Platform and the Swedish ELIXIR node.

CONTACT:
info@nbis.se

For more information, please see the NBIS pages on the SciLifeLab website:

NBIS

National Bioinformatics Infrastructure Sweden (NBIS)

NGI Stockholm consists of two groups; Genomics Production and Genomics Applications Development, and offers state-of-the-art service in the rapidly developing field of massively parallel DNA sequencing.

Genomics Production offers library preparation and high-throughput sequencing followed by data processing and best practice analysis for a variety of well established applications. Genomics Production is Swedac accredited, which ensure that projects are completed in accordance with rigorous quality standards.

Genomics Applications Development collaborates with researchers on applications not supported by Genomics Production.

CONTACT:
NGI Stockholm
support@ngisweden.se

Ellen Sherwood, Head of unit Genomics Production
ellen.sherwood@scilifelab.se

For more information, please see the NGI page on the SciLifeLab website:

National Genomics Infrastructure (NGI)

The in situ sequencing (ISS) unit provides spatially resolved gene expression data for panels of genes at subcellular resolution.

CONTACT:
Chika Yokota
iss@scilifelab.se

For more information, please see the In Situ Sequencing page on the SciLifeLab website:

In Situ Sequencing

The Biochemical and Cellular Assay unit provide the drug discovery projects in the DDD platform with enzymatic and cellular assays using microplate based technologies.

We support the drug discovery projects with analyze of the activity for newly synthesized molecules and biologicals in order to drive structure-activity explorations and thereby enabling the next round of design of a new molecular entities.

CONTACT:
Mathias Färnegårdh
mathias.farnegard@scilifelab.se

For more information, please see the Biochemical and Cellular Assay page on the SciLifeLab website:

Biochemical and Cellular Assay

The medicinal chemists at Hit2Lead design and synthesize new compounds to accelerate academic drug discovery projects.

The goal is to participate in the invention of medicines to treat different diseases. We design and make new compounds to progress our collaborative projects.

Drug discovery is challenging and complex and to be successful you need to understand the underlying cause of the disease, set up system to evaluate the potential and limitations with the compounds made and also to evaluate the approach selected to treat the disease. We do this in collaboration with the other facilities at SciLifeLab Drug Discovery and Development and Swedish academic groups with the goal to develop a new drug.

CONTACT:

Ylva Gravenfors

ylva.gravenfors@scilifelab.se

For more information, please see the Medicinal Chemistry - Hit2Lead on the SciLifeLab website:

Medicinal Chemistry - Hit2Lead